Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Ventas, Inc. (VTR): Why Not Only Old-Timers Should Be Interested In This Specialty REIT

Page 1 of 2

One of the major real estate investment trusts invested in health care facilities, Ventas, Inc. (NYSE:VTR), has risen only 1.13% in 2013, compared to the 12.93% return offered by the Dow Jones Industrial Average.

Ventas, Inc. (NYSE:VTR)

Ventas is a real estate investment trust invested in health care facilities, including senior housing, specialty care facilities, hospitals, and medical office buildings in 46 states and 2 Canadian provinces. As of the end of 2011, the company possessed nearly 1,400 assets in North America. Based on market capitalization, the company is valued at $19.19 billion. Fundamentally, the company’s business model appears strong, with a TTM profit margin of 14.77%.

With the company having deteriorated over 20% from its 2013 highs, is this an opportune moment to snap up a high-quality company, or should investors remain healthy by staying clear of this particular name?


  • Rapid Paced Revenue Growth: In 2003, Ventas reported revenue of $205 million; in 2012, the company announced revenue of $2.48 billion, representing year over year annual growth of 32.28%, a trend that is anticipated to considerably slow into the future with projections placing 2015 revenue at $2.80 billion.  This growth has been a result of aggressive investment by the company in new properties
–Dividend: Currently, the company pays out quarterly dividends of $0.67, which when annualized puts the dividend as yielding 4.09%, a major strength for long-term investors
–Institutional Vote of Confidence: 96% of shares outstanding are held by institutional investors, representing over $19 billion in investment, displaying the confidence some of the largest investors in the world have in the company and its future
–Historic Assets Growth: Assets of the company have grown from $813 million in 2003 to $18.98 billion in 2012, representing the ever-growing asset base of the company; this trend is  anticipated to continue into the future
–Diversified & Established Portfolio: As of the end of 2012, the company’s portfolio consisted of interests in 1,442 properties in the United States and Canada, including 659 senior housing communities, 337 skilled nursing facilities, 47 hospitals, 321 medical office buildings, and 42 other properties in 46 states, the District of Columbia, and two Canadian provinces; with this diversified and established nature comes a greater level of security and predictably for investors


–High Valuation: At the moment, Ventas, Inc. (NYSE:VTR) possesses a price to earnings ratio of 50.74, a price to book ratio of 2.24, and a price to sales ratio of 8.31; all of which indicate a company trading with a high valuation

–Net Debt: The company’s $67.91 million in cash and cash equivalents is outweighed by its $8.41 billion in debt, resulting in a net debt of $8.34 billion, accounting for 40.75% of overall market capitalization, a major financial weakness of the company


  • Dividend Growth: Since implementing their dividend program in 1999, Ventas has consistently raised their dividend payouts and is widely anticipated to sustain this trend into the future
  • Growing Senior US Population: The US population is rapidly growing old, with the number of people over the age of 85 expected to triple the national average in population growth by 2035, and with this aging US population comes the opportunity for Ventas’ senior housing communities segment to prosper and expand to meet rising demand
Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!